Antibody–Oligonucleotide Conjugates (AOC): A Next-Generation Platform for Precision Delivery and Gene Regulation

Against the backdrop of continuously advancing precision medicine, drug development is evolving from traditional small molecules and protein therapeutics toward precise interventions at the nucleic acid level. Antibody–oligonucleotide conjugates (AOCs), which combine the targeting capability of antibodies with the gene-regulatory function of oligonucleotides, are emerging as a major innovation following antibody–drug conjugates (ADCs). They show particularly strong potential in genetic and neuromuscular diseases.

Basic Concept and Structural Components of AOCs

Structurally, AOCs typically consist of three core modules:

● Antibody: Recognizes specific cell or tissue receptors to enable precise targeting

● Linker: Connects the antibody and oligonucleotide, determining stability and release mechanism

● Oligonucleotide: Such as siRNA or antisense oligonucleotides (ASO), used to regulate gene expression

This structure essentially forms a “navigation + functional execution” system, allowing the drug not only to find its target but also to modulate gene expression. This design marks a shift from protein-level targeting to gene-level regulation.

Mechanism of Action: From Precision Delivery to Gene Regulation

The mechanism of AOCs can be divided into four key steps:

1.  Target Recognition

The antibody binds to specific receptors (e.g., TfR1), enabling tissue-specific localization

2.  Receptor-Mediated Endocytosis

The AOC is internalized into the cell

3.  Payload Release

The oligonucleotide is released within endosomal/lysosomal environments

4.  Gene Regulation

Therapeutic effects are achieved through RNA interference or splicing modulation

This mechanism represents a dual breakthrough: precision delivery combined with molecular-level intervention.

Core Advantages of AOCs

Compared with traditional nucleic acid drugs, AOCs offer significant advantages:

● Improved delivery efficiency: Antibody-guided targeting enhances uptake in specific tissues

● Greater tissue selectivity: Reduces exposure in non-target tissues

● Enhanced stability: Lowers degradation risk in vivo

● Higher therapeutic precision: Directly modulates gene expression

In essence, AOCs address the long-standing “delivery bottleneck” of nucleic acid therapeutics.

Key Differences Between AOCs and ADCs

Although often considered an evolution of ADCs, AOCs differ fundamentally:

AOCs function more like a regulatory system, whereas ADCs act as precision weapons.

Main Application Areas

Currently, the most promising applications of AOCs include:

1️⃣ Neuromuscular Diseases

For example, Duchenne muscular dystrophy (DMD), restoring protein function via exon skipping

2️⃣ Genetic Disorders

Targeting single-gene mutations with precision

3️⃣ Central Nervous System Diseases

Overcoming blood–brain barrier limitations through improved delivery

4️⃣ Metabolic Diseases

Regulating key genes in metabolic pathways

AOCs are expanding from rare diseases toward broader therapeutic areas.

Future Development Trends

AOCs are expected to evolve along several directions:

● Multi-target design to enhance efficacy

● Long-acting expression systems to improve durability

● Combination therapies with gene editing or immunotherapy

● Standardized manufacturing to reduce costs

These trends position AOCs as a potential core platform in next-generation precision medicine.

Conclusion

Antibody–oligonucleotide conjugates (AOCs) represent an innovative convergence of antibody engineering and nucleic acid therapeutics. They not only solve the delivery challenges of nucleic acid drugs but also elevate therapeutic intervention from the protein level to gene regulation.

From current developments, AOCs are transitioning from technical validation to clinical translation. As technologies mature and industry ecosystems improve, AOCs are poised to play a critical role in precision medicine and usher in a new era of gene-level therapeutic control.

Dengyue Pharma remains committed to conducting business with integrity, helping people worldwide achieve better health and improved quality of life.